Host gene expression profiling of cervical smear is eligible for cancer risk evaluation.
about
Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience.Study of circulating IgG antibodies to peptide antigens derived from BIRC5 and MYC in cervical cancerGynecologic biopsy for molecular profiling: a review for the interventional radiologistmRNA biomarker detection in liquid-based cytology: a new approach in the prevention of cervical cancer.
P2860
Host gene expression profiling of cervical smear is eligible for cancer risk evaluation.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Host gene expression profiling of cervical smear is eligible for cancer risk evaluation.
@en
Host gene expression profiling of cervical smear is eligible for cancer risk evaluation.
@nl
type
label
Host gene expression profiling of cervical smear is eligible for cancer risk evaluation.
@en
Host gene expression profiling of cervical smear is eligible for cancer risk evaluation.
@nl
prefLabel
Host gene expression profiling of cervical smear is eligible for cancer risk evaluation.
@en
Host gene expression profiling of cervical smear is eligible for cancer risk evaluation.
@nl
P2093
P1476
Host gene expression profiling of cervical smear is eligible for cancer risk evaluation
@en
P2093
Dmitry Trofimov
Ekaterina Shubina
Elina Sabdulaeva
Gennady Sukhikh
Oksana Nepsha
Olga Bourmenskaya
Svetlana Rogovskaya
P304
P356
10.1136/JCLINPATH-2012-201313
P407
P577
2012-12-25T00:00:00Z